Literature DB >> 27721716

Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts.

Cornelia Liedtke1, Hans-Christian Kolberg2.   

Abstract

Systemic therapy of metastatic breast cancer may include chemotherapy, endocrine therapy, and targeted therapies (e.g., antibody-based approaches). These agents may be employed alone or in combination based on the patient's breast cancer subtype. Therefore, characterization of the disease phenotype is necessary and may include biopsy of the metastatic site. Novel therapeutic approaches include immunologic therapies, PARP inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, which are currently under investigation in clinical trials.

Entities:  

Keywords:  Chemotherapy; Clinical trials; Endocrine therapy; Metastatic breast cancer; Molecular breast cancer subgroups; Targeted therapy

Year:  2016        PMID: 27721716      PMCID: PMC5040928          DOI: 10.1159/000447549

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  7 in total

1.  Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet.

Authors:  Cornelia Kolberg-Liedtke; Rachel Wuerstlein; Oleg Gluz; Florian Heitz; Muriel Freudenberger; Elena Bensmann; Andreas du Bois; Ulrike Nitz; Enrico Pelz; Matthias Warm; Monika Ortmann; Elena Sultova; Sara Y Brucker; Ronald E Kates; Tanja Fehm; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2020-12-15       Impact factor: 2.860

2.  Exceptional Responses to Standard Therapy in a Patient with Metastatic HER2-Positive Breast Cancer.

Authors:  Carsten Nieder; Bård Mannsåker; Ellinor Haukland
Journal:  Cureus       Date:  2017-06-29

3.  The discordance pattern of molecular sub-types between primary and metastatic sites in Chinese breast cancer patients.

Authors:  Gaoda Ju; Rongxuan Zhu; Hanting Zhao; Fen Ye; Liaoran Zhang; Chaoyi Lin; Yanqiao Lu; Xiang Zhang; Ning Li; Peng Xue; Lifei Zhu; Hongxia Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

4.  A Systematic Review and Pooled Analysis of Studies of Oral Etoposide in Metastatic Breast Cancer.

Authors:  Ioannis A Voutsadakis
Journal:  Eur J Breast Health       Date:  2018-01-01

5.  A hederagenin saponin isolated from Clematis ganpiniana induces apoptosis in breast cancer cells via the mitochondrial pathway.

Authors:  Lin Cheng; Liang Shi; Jing Wu; Xujie Zhou; Xiaoxia Li; Xi Sun; Lei Zhu; Tian-Song Xia; Qiang Ding
Journal:  Oncol Lett       Date:  2017-11-27       Impact factor: 2.967

6.  Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer.

Authors:  Fenghu Li; Bi Wang; Mingyuan He; Jianying Chang; Jiehui Li; Lang Shan; Heran Wang; Wei Hong; Daiqin Luo; Yang Song; Liyang Liu; Huiqin Li; Li Ran; Tengxiang Chen
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

Review 7.  Implications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer.

Authors:  Joseph T Decker; Jeffrey A Ma; Lonnie D Shea; Jacqueline S Jeruss
Journal:  Cancers (Basel)       Date:  2021-10-25       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.